Healthcare distributor and services company Cardinal Health (NYSE: CAH) reported calendar Q3 2026 (fiscal Q1 2027) results topping the market’s revenue expectations, with sales up 5.5% year on year to $67.51 billion. Its non-GAAP profit of $3.26 per share was 10.9% above analysts’ consensus estimates.
Is now the time to buy CAH? Find out in our full research report (it’s free for active Edge members).
Cardinal Health (CAH) Q3 CY2026 highlights:
- Revenue $67.51 billion vs S&P analysts’ estimates of $66.72 billion (5.5% year-on-year growth, 1.2% beat)
- Adjusted EPS $3.26 vs S&P analysts’ estimates of $2.94 (10.9% beat)
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $12.90 at the midpoint, a 3.2% increase
- Operating margin 1.1%, in line with the same quarter last year
- Market capitalization $62.02 billion
StockStory’s take
Cardinal Health delivered a better-than-expected quarter, with both revenue and non-GAAP profit surpassing Wall Street estimates and a significant positive market reaction. Management attributed this performance to strong demand in its pharmaceutical and specialty solutions segment, continued operational efficiency, and the positive impact of long-term contract renewals. CEO Jason Hollar highlighted the company’s ability to drive growth through disciplined execution and strategic investments, emphasizing that recent renewals with major customers like CVS Health provide a stable foundation for ongoing operational improvement.
Looking ahead, Cardinal Health’s raised full-year adjusted EPS guidance is supported by expectations of sustained demand in specialty pharmaceuticals, ongoing integration of recent acquisitions, and efficiency initiatives in its medical products business. Management cited robust secular trends in home-based care and complex therapies as ongoing tailwinds, while cautioning that industry policy changes and commodity cost pressures remain potential headwinds. CFO Aaron Alt emphasized the importance of operational leverage and disciplined capital allocation, stating that the company’s focus on core distribution, specialty expansion, and supply chain modernization underpins confidence in future performance.
Key insights from management’s remarks
Management pointed to broad-based growth in pharmaceuticals, significant contract renewals, and operational improvements in medical products as core drivers of the latest quarter’s performance and the outlook for the year.
- Specialty segment momentum: Leadership highlighted high demand and growth in specialty pharmaceuticals, particularly in therapeutic areas like urology and oncology, as key to driving both revenue and profit. The integration of Solaris and the MSO platform is expanding reach and capabilities, supporting outperformance in this segment.
- Major contract renewals: The renewal of the CVS Health contract through 2032 and other multi-year agreements with top customers were emphasized as strengthening Cardinal Health’s revenue base and providing long-term stability for investment and planning.
- Medical products operational progress: The global medical products and distribution (GMPD) segment showed improved operational performance, with management citing efficiency gains from the GMPD Improvement Plan and expanded use of AI-driven automation in distribution centers. While revenue was flat, Cardinal Health-branded product growth and cost management contributed positively.
- Synergies from recent acquisitions: Acquisitions in the at-Home business, including the integration of Strive Medical, are delivering on planned synergies and positioning the segment for ongoing growth as demand for home-based care rises.
- Investment in supply chain and technology: Management continues to invest in supply chain modernization, automation, and AI infrastructure across the enterprise, aiming to enhance productivity, customer service, and long-term profitability.
Drivers of future performance
Cardinal Health’s outlook is shaped by continued specialty growth, operational efficiency, and strategic investment across its businesses, while closely monitoring policy and commodity risks.
- Sustained specialty and contract growth: Management expects revenue and profit growth to be underpinned by continued strong demand in specialty pharmaceuticals and the stability provided by major contract renewals. The company is targeting double-digit profit growth in its pharma segment, supported by its Red Oak Sourcing partnership and expanding specialty business.
- Operational efficiency and technology investment: Ongoing supply chain modernization, implementation of AI-driven automation in distribution, and network optimization in medical products are expected to drive margin improvement and productivity, with management targeting operational leverage across segments.
- Exposure to policy and commodity risks: Management acknowledged that regulatory changes, such as updates to reimbursement models and shifts in healthcare policy, along with volatility in petroleum and commodity costs, could affect profitability—especially in the GMPD segment. The company is actively engaging policymakers and adapting business strategies to mitigate these risks.
Catalysts in upcoming quarters
Looking forward, the StockStory team will be watching (1) the pace of specialty segment growth and integration of Solaris and Strive Medical, (2) the impact of major contract renewals on revenue visibility and long-term stability, and (3) operational improvements in the medical products segment, particularly as AI-driven automation and supply chain modernization scale up. Policy developments and commodity cost trends will also be key to monitoring Cardinal Health’s ability to sustain margin improvements.
Cardinal Health currently trades at $269.40, up from $261.93 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Now could be the perfect time to invest in these stocks
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
